2023 Impact Factor: 4.5 2023 CiteScore: 8.0
文章一审周期17.4天,从接收到发表仅2.7天 (据2022年上半年统计数据)。 2021 Impact Factor 6.575 2021 CiteScore 5.8 Time to First Decision 17.4 Days Time to Publication 40 Days 期刊主编 Prof. Dr. Samuel C. Mok 美国 德克萨斯大学安德森癌症中心 研究领域 Cancers 期刊发表与肿瘤类型的基础、转化和临床相关...
2023 Impact Factor: 4.5 2023 CiteScore: 8.0
截止目前,Cancers期刊有超过三至之一的论文被引量10次及以上。手稿处理时间相对较短:一审周期17.9天,从接收到发表仅2.8天 (根据2023年下半年统计数据)。 封面文章精选 点击链接,查看期刊更多封面文章: https://www.mdpi.com/2072-66...
Submission Deadline: 30 April 2023 特刊简介 上下滑动查看更多 非霍奇金淋巴瘤是由成熟淋巴细胞在不同分化阶段恶性转化的复杂过程引起的异质性淋巴肿瘤。对于大多数非霍奇金淋巴瘤亚型,化疗、免疫和/或靶向治疗的进展显著改善了患者的预后。然而...
期刊主题涵盖癌症治疗和免疫疗法、癌症生物标志物、流行病学和预防、肿瘤微环境、癌症病因和筛查、诊断和护理、癌症分子生物学等肿瘤学领域各个方面。目前,期刊已被 SCIE、Scopus 等重要数据库收录。 2022 Impact Factor:5.2 2022 CiteScore:7.4 Time to First Decision:18.2 days Time to Publication:40 Days...
documents published in that journal. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) ...
Nature Reviews Cancer volume 23, pages 631–650 (2023)Cite this article 3344 Accesses 18 Altmetric Metrics details Abstract The genomic simplicity of differentiated cancers derived from thyroid follicular cells offers unique insights into how oncogenic drivers impact tumour phenotype. Essentially, the ...
et al. Low risk of embryonic and other cancers in PIK3CA-related overgrowth spectrum: impact on screening recommendations. Clin. Genet. 104, 554–563 (2023). Article CAS PubMed Google Scholar Gripp, K. W. et al. Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic ...
Cancers 期刊介绍 期刊主题涵盖癌症治疗和免疫疗法、癌症生物标志物、流行病学和预防、肿瘤微环境、癌症病因和筛查、诊断和护理、癌症分子生物学等肿瘤学领域各个方面。目前,期刊已被 SCIE、Scopus 等重要数据库收录。 2023 Impact Factor: 4.5 2023 CiteScore: 8.0...